FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

ペプチドライブラリー

AOD-9604

Anti-Obesity Drug 9604 / Tyr-hGH Fragment 177-191

Weight Loss & Metabolic

AOD-9604 is a synthetic peptide fragment corresponding to amino acids 177-191 of human growth hormone (hGH), modified with a tyrosine residue at the N-terminus. Developed by Metabolic Pharmaceuticals in Australia, it was designed to isolate the lipolytic (fat-burning) activity of hGH without its growth-promoting or diabetogenic effects. Despite failing Phase 2B clinical trials for obesity in 2007, it received TGA approval in Australia as a food-grade supplement and remains widely used in weight management research.

作用機序

Modified fragment of human growth hormone (amino acids 177-191). Stimulates lipolysis and inhibits lipogenesis without growth-promoting or diabetogenic effects.

研究プロトコル

研究目的のみで使用。医療アドバイスではありません。

Research protocols typically use 300-600mcg daily via subcutaneous injection, in the morning on empty stomach.

研究ノート

Clinical Research Status

AOD-9604 completed Phase 2B clinical trials for obesity conducted by Metabolic Pharmaceuticals, which failed to demonstrate statistically significant weight loss over placebo in a 24-week trial of 536 obese patients. The Australian TGA subsequently approved it with GRAS status for use in food products (2014), a controversial decision given the failed efficacy trials. It remains investigational for injectable use and is not FDA-approved for any indication.

Key Published Findings

Early studies in obese Zucker rats and mice demonstrated significant fat reduction without affecting IGF-1 levels or causing the insulin resistance associated with full-length hGH. The peptide stimulates lipolysis and inhibits lipogenesis through interaction with the beta-3 adrenergic receptor pathway. Human trial data showed that while some dose groups trended toward fat loss, the primary endpoint was not met, and the magnitude of effect did not justify further development as a standalone obesity drug.

Safety Profile

AOD-9604 demonstrated an excellent safety profile in clinical trials with no serious adverse events attributed to the drug and no effects on glucose metabolism, IGF-1, or other growth-related markers. Unlike full-length hGH, it does not cause insulin resistance, fluid retention, or joint pain. The fragment does not stimulate growth of bone, cartilage, or other tissues, confirming successful isolation of the lipolytic domain from growth-promoting activity.

Drug Interactions & Contraindications

No significant drug interactions have been documented in clinical trial data. Theoretical synergism exists with other lipolytic agents (beta-agonists, caffeine) though this has not been formally studied. No absolute contraindications have been identified beyond standard peptide precautions (pregnancy, active malignancy). The lack of IGF-1 stimulation means cancer-related contraindications applicable to GH secretagogues do not apply.

Comparison to Related Compounds

Unlike full-length hGH or GH secretagogues (GHRP-6, Ipamorelin, CJC-1295), AOD-9604 does not elevate GH or IGF-1 levels, meaning it cannot cause GH-related side effects but also cannot provide GH's anabolic, recovery, or anti-aging benefits. Compared to tirzepatide and semaglutide, its weight loss efficacy is substantially lower based on available trial data. FRAG 176-191 (without the tyrosine modification) is a related compound sometimes confused with AOD-9604.

Community Observations

Typically dosed at 250-500mcg subcutaneously daily, administered in the morning on an empty stomach to capitalize on fasted lipolysis. Often combined with other fat loss peptides or GH secretagogues to provide complementary mechanisms. Users report modest improvements in localized fat reduction over 8-12 week protocols, though expectations should be tempered by the failed Phase 2B trial results showing limited efficacy as a standalone agent.

半減期

~30-45 minutes

再構成

Bacteriostatic water (BAC)

保存

乾燥粉末

Refrigerate 2-8C up to 24 months.

再溶解

Refrigerate 2-8C. Use within 30 days.

米国法的状況

Research chemical (not FDA-approved)

また知られる名前

Anti-Obesity Drug 9604Tyr-hGH Fragment 177-191

よくある質問

AOD-9604とは何ですか?

AOD-9604 is a synthetic peptide fragment corresponding to amino acids 177-191 of human growth hormone (hGH), modified with a tyrosine residue at the N-terminus. Developed by Metabolic Pharmaceuticals in Australia, it was designed to isolate the lipolytic (fat-burning) activity of hGH without its growth-promoting or diabetogenic effects. Despite failing Phase 2B clinical trials for obesity in 2007, it received TGA approval in Australia as a food-grade supplement and remains widely used in weight management research.

AOD-9604はどのように作用しますか?

Modified fragment of human growth hormone (amino acids 177-191). Stimulates lipolysis and inhibits lipogenesis without growth-promoting or diabetogenic effects.

AOD-9604の米国での規制状況は?

Research chemical (not FDA-approved)

AOD-9604の半減期は?

~30-45 minutes

AOD-9604の別名は?

Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191

ペプチドコンタクトは、研究目的のみのための要約情報を提供しています。私たちはベンダーの文書をホスト、配布、または推奨していません。すべての分析証明書、GMP認定証明書、およびベンダーコミュニケーションは、購入者によって直接要求され、確認される必要があります。このプラットフォーム上の何らかの情報は法的、医学的、または専門的なアドバイスを構成していません。ユーザーは、適切な法律、州法、および連邦法に準拠するためにベンダー資格を検証し、購入前に遵守することに全責任を持つ必要があります。このプラットフォームを使用することで、完全な個人的責任を承認することになります。

完全な免責事項を読む